The influence of coronary stenting with rapamycin-eluting stents on the number of circulating CD4+CD25high+regulatory T-cells

Abstract

Aim. To investigate the effects of coronary stenting with rapamycin-eluting stents on parameters of cell immunity.
Methods. 26 patients (group 1) with stable coronary heart disease and angiographically proved coronary stenosis underwent stenting with rapamycin-eluting stents. The control group (group 2) consisted of 6 patients: 4 patients underwent diagnostic coronaroangiography, 1 patient got a bare metal stent and in 1 patient angioplasty was unsuccessful. Blood samples were obtained before and 1 month after the intervention. The quantity of activated (CD4+CD25low+) and regulatory (CD4+CD25high+) T cells was measured by direct immunofluorescence and flow cytometry. Plasma concentration of IL-10 was determined by ELISA.
Results. In group 1 the percentages of CD4+CD25high+ regulatory T-cells increased significantly one month after stenting, while in group 2 no difference in regulatory T-cell levels before and after the intervention was observed. No changes in total number of leukocytes, relative levels of lymphocytes, CD4+ T-cells, activated CD4+CD25+low T-cells and IL-10 plasma concentration before and after the procedure were detected in both groups.
Conclusion. Rapamycin-eluting stent implantation is associated with a significant increase of circulating CD4+CD25high+ regulatory T-cell level.

References

  1. Serruys P. W., de Jaegere P., Kiemeneij F. et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 1994; 331 (8): 489-495.
  2. Fischrnan D. L., Leon M. B., Baim D. S. et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery sisease. Circulation 1995; 92 (9): 2480-2487.
  3. Popma J. J., Leon M. B., Moses J. W. et al. for the SIRIUS Investigators. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 2004; 110: 3773-3780.
  4. Colombo A., Drzewiecki J. et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788.
  5. Marx S. O., Jayaraman T., Go L. O., Marks A. R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 1995; 76: 412-417.
  6. Klugherz B. D., Llanos G., Lieuallen W. et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis. 2002; 13 (3): 183-188.
  7. Suzuki T., Kopia Gr. et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188-1193.
  8. Sardella G., De Luca L., Di Roma A. et al. Comparison between sirolimus- and paclitaxel-eluting stent in T-cell subsets redistribution. Am. J. Cardiol. 2006; 97 (4): 494-498.
  9. Fehérvari Z., Sakaguchi S. CD4+ Tregs and immune control. J. Clin. Invest. 2004; 114 (9): 1209-1217.
  10. Cools N., Ponsaerts P., Van Tendeloo V. F., Berneman Z. N. Regulatory T cells and human disease. Clin. Dev. Immunol. 2007; 2007:89195.
  11. Ярилин А. А. Естественные регуляторные Т-клетки. Рос. мед. журн. 2007; 1; 43-48.
  12. Baan C. C., van der Mast B. J. et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80 (1): 110-117.
  13. Coenen J. J., Koenen H. J. et al. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107 (3): 1018-1023.
  14. Duggleby R. C., Shaw T. N. et al. CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells. Immunology 2007; 121 (1): 129-139.
  15. Battaglia M., Stabilini A. et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 2006; 177 (12): 8338-8347.
  16. Strauss L., Wniteside T. L. et al. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 2007; 178 (1): 320-329.
  17. Korczak-Kowalska G., Wierzbicki P., Bocian K. et al. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation. Transplant. Proc. 2007; 39 (9): 2721-2723.
  18. Basu S., Golovina T. et al. Cutting edge: Foxp3-mediated induction of pirn 2 allows human T regulatory cells to preferentially expand in rapamycin. J. Immunol. 2008; 180 (9): 5794- 5798.
  19. van Oosterwijk M. F., Juwana H. et al. CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Thl cell development. Int. Immunol. 2007; 19 (6): 713-718.
  20. Hintzen R. Q., de Jong R. et al. Regulation of CD27 expression on subsets of mature T-lymphocytes. J. Immunol. 1993; 151 (5): 2426-2435.
  21. Vignali D. A., Collison L. W., Workman C. J. How regulatory cess work. Nat. Rev. Immunol. 2008; 8: 523-532.

Statistics

Views

Abstract: 141

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2009 Aref'eva T.I., Provatorov S.I., Potekhina A.V., Sokolov V.O., Kukhtina N.B., Samko A.N., Krasnikova T.L., Arefieva T.I., Provatorov S.I., Potekhina A.V., Sokolov V.O., Kukhtina N.B., Samko A.N., Krasnikova T.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies